Clinical trials: Liver Tumour
Colorectal Cancer
Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer
It has been shown that RFA induced systemic tumor antigen-specific T cell responses in human carcinoma. However, there are insufficient studies on the immune modulation of tumor microenviroment (TME) outside of the ablation zone.
- Trial name
- NCT02475889
- Testing
- Hepatic RFA, Primary tumor resection
- Volunteers
- 78 people
- Sponsor
- The First People's Hospital of Changzhou
Cancer of Liver, Hepatocellular Carcinoma
Prospective Cohort of Patients With Hepatocellular Carcinoma in France
Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer.
- Trial name
- CHIEF (NCT04348838)
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome…
- Trial name
- NCT04712643
- Testing
- Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE)
- Where
- 40 sites in China, Japan
- Volunteers
- 342 people
- Sponsor
- Hoffmann-La Roche
Liver Neoplasms
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
This study will evaluate the safety and effects of vaccine treatment plus radiation to the liver in patients with solid tumors that have spread to the liver.
- Trial name
- NCT00081848
- Testing
- rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
The prognosis of patients with metastatic right-sided colon cancer is worse than that of patients with metastatic left-sided cancer.
- Trial name
- NCT04525326
- Testing
- Cetuximab, Bevacizumab, mFOLFOX/FOLFIRI ( Standard Chemotherapy)
- Volunteers
- 584 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Liver Cancer
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
This study is for people with cancer of the liver that cannot be completely removed by surgery. This study involves giving the drugs mitomycin-C and cisplatin, into an artery in the liver.
- Trial name
- NCT00183885
- Testing
- mitomycin-c, cisplatin
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Southern California
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Hepatocellular Carcinoma, Hepatoma
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2 expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor activity of intravenous TKM-080301 in subjects with…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Adult
- Trial name
- NCT02191878
- Testing
- TKM-080301
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Melanoma, Liver Metastasis
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
- Trial name
- NCT00833807
- Testing
- Nab-Paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatic Cancer, Hepatic Neoplasm
Endoscopic Ultrasound Guided Liver Biopsy
This is a prospective study to determine the optimal technique for obtaining liver tissue with a smaller caliber (22 gauge) needle and whether a good core biopsy can be obtained without the use of suction and secondly to…
- Conditions
- Hepatic Cancer, Hepatic Neoplasm, Hepatic Carcinoma
- Trial name
- NCT03307811
- Testing
- 22 gauge needle liver biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- AdventHealth
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for liver cancer.
- Trial name
- NCT02447263
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma, Liver Cirrhosis
The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma
The aim of this work is to study the role of long non-coding RNAs WRAP53 and urothelial carcinoma-associated 1 (UCA1) as potential biomarkers in diagnosis of hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Diagnoses Disease
- Trial name
- NCT05088811
- Testing
- WRAP53, UCA-1
- Where
- 2 sites in Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Adult Hepatocellular Carcinoma, Localized Resectable Adult Liver Carcinoma
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection.
- Trial name
- NCT01395030
- Testing
- Computed Tomography, 18F-fluoromethylcholine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Queen's Medical Center
Hepatocellular Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
This is a non-randomized, prospective, pilot, Multicenter Study of Drug-eluting bead transarterial chemoembolization (DEB-TACE) using Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat hepatocellular carcinoma (HCC).
- Trial name
- MIRACLE I (NCT01798134)
- Testing
- TANDEM™
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma
- Trial name
- NCT05621499
- Testing
- HAIC, Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer Metastatic
Ablation vs Resection of Colorectal Cancer Liver Metastases
230 patients with colorectal cancer liver metastases will be randomly assigned to resection or thermal ablation.
- Trial name
- NEW-COMET (NCT05129787)
- Testing
- Surgical resection, Thermal ablation
- Where
- Norway
- Volunteers
- 230 people
- Sponsor
- Oslo University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.